Reilly Financial Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Reilly Financial Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,000	Closed	-$5K	–	1032
2019 Q1	$5K	Sell	1,000 -300	-23%	-$1.36K	﹤0.01%	807
2018 Q4	$5K	Hold	1,300	–	–	﹤0.01%	770
2018 Q3	$8K	Hold	1,300	–	–	﹤0.01%	759
2018 Q2	$10K	Hold	1,300	–	–	﹤0.01%	677
2018 Q1	$10K	Hold	1,300	–	–	﹤0.01%	659
2017 Q4	$8K	Hold	1,300	–	–	﹤0.01%	709
2017 Q3	$10K	Hold	1,300	–	–	﹤0.01%	640
2017 Q2	$9K	Hold	1,300	–	–	﹤0.01%	667
2017 Q1	$12K	Hold	1,300	–	–	﹤0.01%	587
2016 Q4	$11K	Sell	1,300 -100	-7%	-$739	﹤0.01%	551
2016 Q3	$9K	Buy	+1,400	New	+$8.46K	﹤0.01%	559

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Reilly Financial Advisors's PGNX Position: Q2 2019 in Review

Reilly Financial Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2019, closing a stake of 1,000 shares — an estimated $5K sold.

Reilly Financial Advisors first reported a position in PGNX in Q3 2016 and held it in 11 quarters. The position peaked at $12K in Q1 2017. 142 funds tracked by Wall St. Rank hold PGNX as of Q2 2019.

Reilly Financial Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2019 after selling out during the quarter.
Reilly Financial Advisors sold 1,000 Progenics Pharmaceuticals Inc shares in Q2 2019, an estimated $5K.
Reilly Financial Advisors first reported a position in Progenics Pharmaceuticals Inc in Q3 2016 and held it in 11 quarters.
Reilly Financial Advisors's Progenics Pharmaceuticals Inc position peaked at $12K in Q1 2017.
142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2019.

Based on Reilly Financial Advisors's 13F filing for Q2 2019, filed 23 Jul 2019.